Enabling Tissue Targeting of Therapies
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Create a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2024
Jan 2022
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
